Recombivax Hb Injection, Suspension
NDC Package 83703-085-02
Package Information
Recombivax Hb (hepatitis b vaccine (recombinant)) injection is classified as a
- actively acquired immunity - [pe] (physiologic effect)
- hepatitis b vaccines - [cs]
- inactivated hepatitis b virus vaccine - [epc] (established pharmacologic class)
- vaccines administered via intramuscular; subcutaneous route. This formulation utilizes a injection, suspension delivery system. Marketed by Bamboo Us Bidco Llc, this product is identified by NDC 83703-085 and is authorized under FDA application BLA101066.
Identification & Billing
- RxCUI: 830243 - hepatitis B vaccine (recombinant) adult (HepB) 10 MCG in 1 ML Prefilled Syringe
- RxCUI: 830243 - 1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Prefilled Syringe
- RxCUI: 830243 - hepatitis B surface antigen vaccine 0.01 MG per 1 ML Prefilled Syringe
- RxCUI: 830243 - hepatitis B surface antigen vaccine 10 MCG per 1 ML Prefilled Syringe
- RxCUI: 830245 - RECOMBIVAX HB adult vaccine 1 ML Prefilled Syringe
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Regulatory & Marketing
Hierarchy Structure
- 83703 - Bamboo Us Bidco Llc
- 83703-085 - Recombivax Hb
- 83703-085-02 - .5 mL in 1 SYRINGE
- 83703-085 - Recombivax Hb
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83703-085-02 identifies a specific commercial package of .5 ml in 1 syringe of Recombivax Hb, a vaccine label labeled by Bamboo Us Bidco Llc. This injection, suspension is formulated for intramuscular; subcutaneous use and contains hepatitis b virus subtype adw hbsag surface protein antigen as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bamboo Us Bidco Llc on February 26, 2026. The current certification is valid through December 31, 2027.
How is this Bamboo Us Bidco Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83703008502. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.